AR086344A1 - Metodos de tratamiento o prevencion de trastornos relacionados con el colesterol - Google Patents
Metodos de tratamiento o prevencion de trastornos relacionados con el colesterolInfo
- Publication number
- AR086344A1 AR086344A1 ARP120101655A ARP120101655A AR086344A1 AR 086344 A1 AR086344 A1 AR 086344A1 AR P120101655 A ARP120101655 A AR P120101655A AR P120101655 A ARP120101655 A AR P120101655A AR 086344 A1 AR086344 A1 AR 086344A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- pcsk9
- cholesterol
- pharmaceutically acceptable
- prevention
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 235000012000 cholesterol Nutrition 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 5
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 abstract 4
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 abstract 4
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008180 pharmaceutical surfactant Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Métodos de tratamiento o prevención de trastornos relacionados con el colesterol, tales como hipercolesterolemia, hiperlipidemia o dislipidemia, usando anticuerpos contra la proproteína convertasa subtilisina/kexina tipo 9 (PCSK9). También se describen formulaciones y métodos para producir dichas formulaciones.Reivindicación 79: Una formulación estable, caracterizada porque comprende al menos un anticuerpo monoclonal que se une específicamente a PCSK9, en donde la PCSK9 comprende los aminoácidos de la SEQ ID Nº 1, el anticuerpo monoclonal en una cantidad de entre aproximadamente 40 mg/ml y aproximadamente 300 mg/mI, y una solución amortiguadora farmacéuticamente aceptable en una cantidad de entre aproximadamente 0,05 mM y aproximadamente 40 mM, y un agente tensioactivo farmacéuticamente aceptable en una cantidad que comprende entre aproximadamente 0,01% p/v y aproximadamente 20% p/v, y al menos un estabilizante farmacéuticamente aceptable de entre aproximadamente 0,5% p/v y aproximadamente 10% p/v, en donde la formulación estable tiene un pH de entre aproximadamente 4,0 y aproximadamente 6,0. Reivindicación 98: La formulación estable de cualquiera de las reivindicaciones 79 a 97, caracterizada porque el anticuerpo monoclonal se selecciona del grupo que consiste de 21B12, 31H4, 8A3, 11F1 y 8A1.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161484610P | 2011-05-10 | 2011-05-10 | |
US201161562303P | 2011-11-21 | 2011-11-21 | |
US201261595526P | 2012-02-06 | 2012-02-06 | |
US201261614417P | 2012-03-22 | 2012-03-22 | |
US201261642363P | 2012-05-03 | 2012-05-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR086344A1 true AR086344A1 (es) | 2013-12-04 |
Family
ID=46124771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120101655A AR086344A1 (es) | 2011-05-10 | 2012-05-10 | Metodos de tratamiento o prevencion de trastornos relacionados con el colesterol |
Country Status (36)
Country | Link |
---|---|
US (2) | US20130064825A1 (es) |
EP (2) | EP3597218A1 (es) |
JP (3) | JP6166717B2 (es) |
KR (4) | KR102528752B1 (es) |
CN (3) | CN113786482A (es) |
AP (1) | AP2013007303A0 (es) |
AR (1) | AR086344A1 (es) |
AU (4) | AU2012253434B2 (es) |
BR (1) | BR112013028819A2 (es) |
CA (1) | CA2835294C (es) |
CL (2) | CL2013003214A1 (es) |
CR (1) | CR20130640A (es) |
CY (1) | CY1122967T1 (es) |
DK (1) | DK2707029T3 (es) |
EA (1) | EA031228B1 (es) |
ES (1) | ES2781749T3 (es) |
HR (1) | HRP20200545T1 (es) |
HU (1) | HUE049018T2 (es) |
IL (4) | IL288048B1 (es) |
JO (2) | JOP20200043A1 (es) |
LT (1) | LT2707029T (es) |
ME (1) | ME03765B (es) |
MX (2) | MX2013013187A (es) |
MY (2) | MY173860A (es) |
PE (3) | PE20181790A1 (es) |
PH (1) | PH12019501274A1 (es) |
PL (1) | PL2707029T3 (es) |
PT (1) | PT2707029T (es) |
RS (1) | RS60292B1 (es) |
SG (1) | SG194855A1 (es) |
SI (1) | SI2707029T1 (es) |
TW (4) | TWI610683B (es) |
UA (2) | UA114602C2 (es) |
UY (1) | UY34063A (es) |
WO (1) | WO2012154999A1 (es) |
ZA (1) | ZA201309173B (es) |
Families Citing this family (154)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
BR112013018740A2 (pt) | 2011-01-28 | 2019-01-08 | Sanofi Sa | anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos |
EP2731623A1 (en) * | 2011-07-14 | 2014-05-21 | Pfizer Inc | Treatment with anti-pcsk9 antibodies |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
CN103930444B (zh) | 2011-09-16 | 2020-08-04 | 瑞泽恩制药公司 | 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法 |
EA039663B1 (ru) * | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
RU2015101113A (ru) | 2012-06-15 | 2016-08-10 | Дженентек, Инк. | Антитела против pcsk9, составы, дозы и способы применения |
KR20150041662A (ko) | 2012-08-13 | 2015-04-16 | 리제너론 파아마슈티컬스, 인크. | Ph-의존적 결합 특성을 갖는 항-pcsk9 항체 |
EP2968985A2 (en) * | 2013-03-15 | 2016-01-20 | Amgen, Inc. | Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 |
GB2523527A (en) * | 2013-04-05 | 2015-09-02 | Weiming Xu | Screen compounds for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) |
TWI679019B (zh) * | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗il-4/抗il-13之雙特異性抗體調配物 |
US10111953B2 (en) * | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
EP2810955A1 (en) | 2013-06-07 | 2014-12-10 | Sanofi | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
US10494442B2 (en) | 2013-06-07 | 2019-12-03 | Sanofi Biotechnology | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
EP2862877A1 (en) | 2013-10-18 | 2015-04-22 | Sanofi | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
CA2916259C (en) * | 2013-06-28 | 2024-02-20 | Amgen Inc. | Methods for treating homozygous familial hypercholesterolemia |
CN104371019B (zh) * | 2013-08-13 | 2019-09-10 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
EP3689913B1 (en) * | 2013-10-11 | 2022-03-23 | Sanofi Biotechnology | Use of a pcsk9 inhibitor to treat hyperlipidemia |
PT3055333T (pt) * | 2013-10-11 | 2020-03-11 | Regeneron Pharma | Uso de um inibidor de pcsk9 para tratar a hiperlipidemia |
EP3882273A1 (en) * | 2013-11-12 | 2021-09-22 | Sanofi Biotechnology | Dosing regimens for use with pcsk9 inhibitors |
US20150139987A1 (en) * | 2013-11-20 | 2015-05-21 | Cymabay Therapeutics, Inc. | Treatment of homozygous familial hypercholesterolemia |
EP2975058A1 (en) * | 2014-07-15 | 2016-01-20 | Kymab Limited | Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations |
US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
TWI713444B (zh) * | 2013-12-17 | 2020-12-21 | 英商凱美寶有限公司 | 人類標靶 |
US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
US9051378B1 (en) | 2014-07-15 | 2015-06-09 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
EP2886558A1 (en) * | 2013-12-17 | 2015-06-24 | Kymab Limited | Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations |
US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
DE112014005747T5 (de) * | 2013-12-17 | 2016-10-06 | Kymab Limited | Antikörper zur Verwendung bei der Behandlung von Zuständen, die mit spezifischen PCSK9 Varianten in spezifischen Patientenpopulationen in Beziehung stehen |
WO2015092393A2 (en) * | 2013-12-17 | 2015-06-25 | Kymab Limited | Human targets |
US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
RU2016137264A (ru) * | 2014-02-21 | 2018-03-26 | МЕДИММЬЮН, ЭлЭлСи | Слияния антитела к pcsk9~glp-1 и способы применения |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
WO2015142668A1 (en) * | 2014-03-17 | 2015-09-24 | Sanofi | Methods for reducing cardiovascular risk |
US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
MX367478B (es) | 2014-03-20 | 2019-08-23 | Cymaby Therapeutics Inc | Tratamiento de enfermedades colestasicas intrahepaticas. |
KR102374499B1 (ko) | 2014-04-11 | 2022-03-14 | 사이머베이 쎄라퓨틱스, 인코퍼레이티드 | Nafld 및 nash 의 치료 |
US10722655B2 (en) | 2014-05-07 | 2020-07-28 | Amgen Inc. | Autoinjector with shock reducing elements |
CN106470716B (zh) | 2014-06-03 | 2020-07-17 | 安姆根有限公司 | 可控制药物递送系统和使用方法 |
EP3154968B1 (en) | 2014-06-11 | 2020-08-05 | SpecGx LLC | Oxidative dearomatization of berbines |
AU2015289874A1 (en) * | 2014-07-14 | 2017-02-02 | Amgen Inc. | Crystalline antibody formulations |
MX2017000526A (es) * | 2014-07-14 | 2017-08-02 | Amgen Inc | Formulaciones de anticuerpos cristalinos. |
EP3332790A1 (en) * | 2014-07-15 | 2018-06-13 | Kymab Limited | Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations |
US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
EP4328245A3 (en) * | 2014-07-15 | 2024-06-05 | Kymab Ltd. | Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations |
JP6912374B2 (ja) * | 2014-07-16 | 2021-08-04 | サノフィ・バイオテクノロジー | 高コレステロール血症を有する高心血管リスク患者を処置するための方法 |
CA2955294A1 (en) | 2014-07-16 | 2016-01-21 | Sanofi Biotechnology | Methods for treating patients with heterozygous familial hypercholesterolemia (hefh) |
CA2957960C (en) | 2014-10-14 | 2023-08-22 | Amgen, Inc. | Drug injection device with visual and audible indicators |
WO2016061551A1 (en) * | 2014-10-17 | 2016-04-21 | Amgen Inc. | Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies |
EA038462B1 (ru) | 2014-10-23 | 2021-08-31 | Эмджен Инк. | Снижение вязкости фармацевтических составов |
EP3233159B1 (en) | 2014-12-19 | 2020-03-04 | Amgen Inc. | Drug delivery device with live button or user interface field |
JP6484345B2 (ja) | 2015-02-17 | 2019-03-20 | アムジエン・インコーポレーテツド | 固定及び/または戻りが真空によって支援された薬物送達装置 |
EP3258963A1 (en) * | 2015-02-18 | 2017-12-27 | Universität Zürich | Acetylated pcsk9 |
US11806509B2 (en) | 2015-02-27 | 2023-11-07 | Amgen Inc. | Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement |
RS62224B1 (sr) | 2015-03-02 | 2021-09-30 | Medlab Clinical U S Inc | Transmukozalni i transdermalni sistemi dostave |
WO2016169454A1 (zh) * | 2015-04-21 | 2016-10-27 | 舒泰神(北京)生物制药股份有限公司 | 一种神经生长因子组合物及注射粉剂 |
US20170044516A1 (en) | 2015-08-11 | 2017-02-16 | Industrial Technology Research Institute | Biochemistry reactive material and device for eliminating electronegative low-density lipoprotein (ldl) and method for treating blood or plasma ex vivo to eliminate electronegative low-density lipoprotein therein |
KR20180034672A (ko) | 2015-08-18 | 2018-04-04 | 리제너론 파아마슈티컬스, 인크. | 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체 |
US10821106B2 (en) | 2015-08-21 | 2020-11-03 | Srx Cardio, Llc | Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity |
US10865185B2 (en) | 2015-08-21 | 2020-12-15 | Srx Cardio, Llc | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity |
US10568882B2 (en) | 2015-08-21 | 2020-02-25 | Srx Cardio, Llc | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
CN106810609A (zh) | 2015-11-27 | 2017-06-09 | 苏州君盟生物医药科技有限公司 | 抗pcsk9抗体及其应用 |
US11351308B2 (en) | 2015-12-09 | 2022-06-07 | Amgen Inc. | Auto-injector with signaling cap |
US10793643B2 (en) | 2015-12-31 | 2020-10-06 | Jiangsu Hengrui Medicine Co., Ltd. | PCSK9 antibody, antigen-binding fragment thereof, and medical application thereof |
EP3401336A4 (en) | 2016-01-05 | 2020-01-22 | Jiangsu Hengrui Medicine Co., Ltd. | PCSK9 ANTIBODIES, ANTI-BINDING FRAGMENT THEREOF AND MEDICAL USES THEREOF |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
US20190119236A1 (en) | 2016-02-23 | 2019-04-25 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
EP4035711A1 (en) | 2016-03-15 | 2022-08-03 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
US11541168B2 (en) | 2016-04-29 | 2023-01-03 | Amgen Inc. | Drug delivery device with messaging label |
US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
GB201608323D0 (en) | 2016-05-12 | 2016-06-29 | Ucb Biopharma Sprl | Pharmaceutical compositions |
US10988284B2 (en) | 2016-05-13 | 2021-04-27 | Amgen Inc. | Vial sleeve assembly |
EP3458988B1 (en) | 2016-05-16 | 2023-10-18 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
WO2017200715A1 (en) * | 2016-05-19 | 2017-11-23 | Cymabay Therapeutics, Inc. | Treatment of severe hyperlipidemia |
EP3465124A1 (en) | 2016-06-03 | 2019-04-10 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
EP3478342A1 (en) | 2016-07-01 | 2019-05-08 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
SG10201912565QA (en) | 2016-09-29 | 2020-02-27 | Amgen Inc | Low-viscosity antigen binding proteins and methods of making them |
WO2018067987A1 (en) | 2016-10-06 | 2018-04-12 | Amgen Inc. | Reduced viscosity protein pharmaceutical formulations |
US20200261643A1 (en) | 2016-10-25 | 2020-08-20 | Amgen Inc. | On-body injector |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
JOP20190112A1 (ar) * | 2016-11-14 | 2019-05-14 | Amgen Inc | علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي |
CN108239150A (zh) | 2016-12-24 | 2018-07-03 | 信达生物制药(苏州)有限公司 | 抗pcsk9抗体及其用途 |
AU2018210301A1 (en) | 2017-01-17 | 2019-08-01 | Amgen Inc. | Injection devices and related methods of use and assembly |
US11369736B2 (en) | 2017-02-17 | 2022-06-28 | Amgen Inc. | Cannula insertion and retraction mechanisms |
MX2019009625A (es) | 2017-02-17 | 2019-10-09 | Amgen Inc | Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje. |
JP7377596B2 (ja) * | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
AU2018229724A1 (en) * | 2017-03-06 | 2019-10-31 | Merck Patent Gmbh | Aqueous anti-PD-L1 antibody formulation |
WO2018165143A1 (en) | 2017-03-06 | 2018-09-13 | Amgen Inc. | Drug delivery device with activation prevention feature |
EP3592402A1 (en) | 2017-03-07 | 2020-01-15 | Amgen Inc. | Needle insertion by overpressure |
MX2019010671A (es) | 2017-03-09 | 2019-10-21 | Amgen Inc | Mecanismo de insercion para dispositivo de administracion de farmacos. |
BR112019020053B1 (pt) | 2017-03-28 | 2023-10-10 | Amgen Inc | Máquina para acoplar uma haste de êmbolo a um conjunto de seringa e método de utilização da referida máquina |
KR102401796B1 (ko) | 2017-04-13 | 2022-05-25 | 카딜라 핼쓰캐어 리미티드 | 신규의 펩타이드 기재 pcsk9 백신 |
US11904143B2 (en) | 2017-06-08 | 2024-02-20 | Amgen Inc. | Torque driven drug delivery device |
AU2018280054B2 (en) | 2017-06-08 | 2023-07-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
CA3063920A1 (en) | 2017-06-22 | 2018-12-27 | Amgen Inc. | Device activation impact/shock reduction |
US11395880B2 (en) | 2017-06-23 | 2022-07-26 | Amgen Inc. | Electronic drug delivery device |
JP2020532491A (ja) * | 2017-06-30 | 2020-11-12 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Jiangsu Hengrui Medicine Co., Ltd. | Pcsk−9抗体を含む医薬組成物及びその使用 |
MA49562A (fr) | 2017-07-14 | 2020-05-20 | Amgen Inc | Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion |
EP3655063A1 (en) | 2017-07-21 | 2020-05-27 | Amgen Inc. | Gas permeable sealing member for drug container and methods of assembly |
EP4085942A1 (en) | 2017-07-25 | 2022-11-09 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
US11484648B2 (en) | 2017-07-25 | 2022-11-01 | Amgen Inc. | Drug delivery device with container access system and related method of assembly |
MA49838A (fr) | 2017-08-09 | 2020-06-17 | Amgen Inc | Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre |
EP3668567A1 (en) | 2017-08-18 | 2020-06-24 | Amgen Inc. | Wearable injector with sterile adhesive patch |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
MA50611A (fr) | 2017-10-04 | 2020-08-12 | Amgen Inc | Adaptateur d'écoulement destiné à un dispositif d'administration de médicament |
WO2019070552A1 (en) | 2017-10-06 | 2019-04-11 | Amgen Inc. | DRUG DELIVERY DEVICE COMPRISING A LOCKOUT ASSEMBLY AND ASSOCIATED ASSEMBLY METHOD |
US11464903B2 (en) | 2017-10-09 | 2022-10-11 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
EP3703778A1 (en) | 2017-11-03 | 2020-09-09 | Amgen Inc. | System and approaches for sterilizing a drug delivery device |
US20200338271A1 (en) | 2017-11-06 | 2020-10-29 | Amgen Inc. | Fill-finish assemblies and related methods |
CA3079197A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Drug delivery device with placement and flow sensing |
CN116832271A (zh) | 2017-11-10 | 2023-10-03 | 安进公司 | 用于药物递送装置的柱塞 |
MX2020004996A (es) | 2017-11-16 | 2020-08-27 | Amgen Inc | Un mecanismo de pestillo de puerta para un dispositivo de administracion de farmacos. |
JP6639463B2 (ja) * | 2017-12-21 | 2020-02-05 | アムジエン・インコーポレーテツド | ホモ接合性家族性高コレステロール血症の治療方法 |
CN110464842B (zh) * | 2018-05-11 | 2022-10-14 | 信达生物制药(苏州)有限公司 | 包含抗pcsk9抗体的制剂及其用途 |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
US20210260279A1 (en) | 2018-07-24 | 2021-08-26 | Amgen Inc. | Hybrid drug delivery devices with optional grip portion and related method of preparation |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
MA53379A (fr) | 2018-07-24 | 2021-06-02 | Amgen Inc | Dispositifs d'administration pour l'administration de médicaments |
WO2020023451A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
US20210228797A1 (en) | 2018-07-31 | 2021-07-29 | Amgen Inc. | Fluid path assembly for a drug delivery device |
CA3110346A1 (en) * | 2018-08-24 | 2020-02-27 | Esperion Therapeutics, Inc. | Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses |
AU2019347710A1 (en) | 2018-09-24 | 2021-02-04 | Amgen Inc. | Interventional dosing systems and methods |
CA3110371A1 (en) | 2018-09-28 | 2020-04-02 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
MA53815A (fr) | 2018-10-02 | 2022-01-05 | Amgen Inc | Systèmes d'injection pour administration de médicament avec transmission de force interne |
US20210338936A1 (en) | 2018-10-05 | 2021-11-04 | Amgen Inc. | Drug delivery device having dose indicator |
US20200114082A1 (en) | 2018-10-15 | 2020-04-16 | Amgen Inc. | Drug delivery device having damping mechanism |
TW202031306A (zh) | 2018-10-15 | 2020-09-01 | 美商安進公司 | 用於藥物遞送裝置之平台組裝方法 |
WO2020091956A1 (en) | 2018-11-01 | 2020-05-07 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
WO2020091981A1 (en) | 2018-11-01 | 2020-05-07 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
JOP20210193A1 (ar) | 2019-01-18 | 2023-01-30 | Astrazeneca Ab | مثبطات pcsk9 وطرق استخدامها |
CA3129901A1 (en) | 2019-02-18 | 2020-08-27 | Eli Lilly And Company | Therapeutic antibody formulation |
AU2020263289A1 (en) | 2019-04-24 | 2021-09-16 | Amgen Inc. | Syringe sterilization verification assemblies and methods |
US20220273887A1 (en) | 2019-08-23 | 2022-09-01 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
EP4341161A1 (en) | 2021-05-21 | 2024-03-27 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
JP2023012450A (ja) * | 2021-07-13 | 2023-01-25 | 学校法人福岡大学 | 抗体と遺伝子に結合能を有するポリペプチド |
CN114438075A (zh) * | 2022-02-25 | 2022-05-06 | 刘博巽 | 一种枯草芽孢杆菌前蛋白酶9靶向结合蛋白的筛选方法与应用 |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3180193A (en) | 1963-02-25 | 1965-04-27 | Benedict David | Machines for cutting lengths of strip material |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
JPS58166634A (ja) | 1982-03-29 | 1983-10-01 | Toshiba Corp | 有機溶媒電池用正極 |
JPS58166633A (ja) | 1982-03-29 | 1983-10-01 | Toshiba Corp | 有機溶媒電池用正極 |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
JPS62170639A (ja) | 1986-01-22 | 1987-07-27 | 株式会社システムメンテナンス | 防蟻板の取付け工法 |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
FR2664073A1 (fr) | 1990-06-29 | 1992-01-03 | Thomson Csf | Moyens de marquage d'objets, procede de realisation et dispositif de lecture. |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
CA2090473A1 (en) | 1990-08-29 | 1992-03-01 | Robert M. Kay | Homologous recombinatin in mammalian cells |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
US5766886A (en) | 1991-12-13 | 1998-06-16 | Xoma Corporation | Modified antibody variable domains |
NZ253943A (en) | 1992-06-18 | 1997-01-29 | Genpharm Int | Transfering polynucleotides into eukaryotic cells using co-lipofection complexes of a cationic lipid and the polynucleotide |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
CA2230759C (en) | 1995-08-29 | 2012-02-21 | Kirin Beer Kabushiki Kaisha | Chimeric animal and method for producing the same |
ATE387495T1 (de) | 1996-12-03 | 2008-03-15 | Amgen Fremont Inc | Vollkommen humane antikörper die egfr binden |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
CA2407956A1 (en) | 2000-05-03 | 2001-11-08 | Amgen Inc. | Modified peptides as therapeutic agents |
US20030170289A1 (en) * | 2001-11-14 | 2003-09-11 | Guohua Chen | Injectable depot compositions and uses thereof |
CN1897918A (zh) * | 2003-11-17 | 2007-01-17 | 阿尔萨公司 | 包含两亲性分子作为混悬载体的组合物和剂型 |
EP1977763A4 (en) * | 2005-12-28 | 2010-06-02 | Chugai Pharmaceutical Co Ltd | STABILIZER PREPARATION CONTAINING ANTIBODIES |
CN101600457B (zh) * | 2007-01-09 | 2014-01-08 | 惠氏公司 | 抗il-13抗体调配物和其用途 |
AU2008232902B2 (en) * | 2007-03-30 | 2013-10-03 | Medlmmune, Llc | Antibody formulation |
JOP20080381B1 (ar) * | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
WO2009055783A2 (en) * | 2007-10-26 | 2009-04-30 | Schering Corporation | Anti-pcsk9 and methods for treating lipid and cholesterol disorders |
AR070316A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
EP3011953A1 (en) * | 2008-10-29 | 2016-04-27 | Ablynx N.V. | Stabilised formulations of single domain antigen binding molecules |
JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
WO2011028938A1 (en) * | 2009-09-02 | 2011-03-10 | Alnylam Pharmaceuticals, Inc. | Methods for lowering serum cholestrol in a subject using inhibition of pcsk9 |
SG10201604093XA (en) * | 2010-01-15 | 2016-07-28 | Kirin Amgen Inc | Antibody formulation and therapeutic regimens |
WO2011109415A2 (en) * | 2010-03-02 | 2011-09-09 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
JP5782185B2 (ja) | 2012-06-01 | 2015-09-24 | 日本電信電話株式会社 | パケット転送処理方法およびパケット転送処理装置 |
JP6071725B2 (ja) | 2013-04-23 | 2017-02-01 | カルソニックカンセイ株式会社 | 電気自動車の駆動力制御装置 |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
US11284893B2 (en) | 2019-04-02 | 2022-03-29 | Covidien Lp | Stapling device with articulating tool assembly |
-
2011
- 2011-05-10 JO JOP/2020/0043A patent/JOP20200043A1/ar unknown
-
2012
- 2012-05-10 SG SG2013082854A patent/SG194855A1/en unknown
- 2012-05-10 EP EP19175489.4A patent/EP3597218A1/en active Pending
- 2012-05-10 LT LTEP12722044.0T patent/LT2707029T/lt unknown
- 2012-05-10 KR KR1020217027670A patent/KR102528752B1/ko active IP Right Grant
- 2012-05-10 CA CA2835294A patent/CA2835294C/en active Active
- 2012-05-10 MY MYPI2013004036A patent/MY173860A/en unknown
- 2012-05-10 KR KR1020207019200A patent/KR20200086745A/ko active Application Filing
- 2012-05-10 IL IL288048A patent/IL288048B1/en unknown
- 2012-05-10 PE PE2018001494A patent/PE20181790A1/es unknown
- 2012-05-10 WO PCT/US2012/037394 patent/WO2012154999A1/en active Application Filing
- 2012-05-10 EP EP12722044.0A patent/EP2707029B1/en active Active
- 2012-05-10 US US13/469,032 patent/US20130064825A1/en active Pending
- 2012-05-10 UA UAA201314464A patent/UA114602C2/uk unknown
- 2012-05-10 IL IL311262A patent/IL311262A/en unknown
- 2012-05-10 CN CN202110835168.4A patent/CN113786482A/zh active Pending
- 2012-05-10 EA EA201391668A patent/EA031228B1/ru active Protection Beyond IP Right Term
- 2012-05-10 PE PE2023003011A patent/PE20240547A1/es unknown
- 2012-05-10 TW TW104120418A patent/TWI610683B/zh active
- 2012-05-10 JP JP2014510478A patent/JP6166717B2/ja active Active
- 2012-05-10 SI SI201231760T patent/SI2707029T1/sl unknown
- 2012-05-10 MY MYPI2018000605A patent/MY198324A/en unknown
- 2012-05-10 PT PT127220440T patent/PT2707029T/pt unknown
- 2012-05-10 JO JOP/2012/0112A patent/JO3520B1/ar active
- 2012-05-10 ME MEP-2020-67A patent/ME03765B/me unknown
- 2012-05-10 BR BR112013028819A patent/BR112013028819A2/pt not_active Application Discontinuation
- 2012-05-10 TW TW101116742A patent/TWI609695B/zh active
- 2012-05-10 AU AU2012253434A patent/AU2012253434B2/en active Active
- 2012-05-10 AP AP2013007303A patent/AP2013007303A0/xx unknown
- 2012-05-10 PL PL12722044T patent/PL2707029T3/pl unknown
- 2012-05-10 KR KR1020237014430A patent/KR20230066480A/ko not_active Application Discontinuation
- 2012-05-10 ES ES12722044T patent/ES2781749T3/es active Active
- 2012-05-10 UA UAA201703902A patent/UA126229C2/uk unknown
- 2012-05-10 TW TW109115264A patent/TWI809272B/zh active
- 2012-05-10 MX MX2013013187A patent/MX2013013187A/es unknown
- 2012-05-10 DK DK12722044.0T patent/DK2707029T3/da active
- 2012-05-10 HU HUE12722044A patent/HUE049018T2/hu unknown
- 2012-05-10 PE PE2013002471A patent/PE20141159A1/es not_active Application Discontinuation
- 2012-05-10 CN CN201710556773.1A patent/CN107261139A/zh active Pending
- 2012-05-10 RS RS20200403A patent/RS60292B1/sr unknown
- 2012-05-10 UY UY0001034063A patent/UY34063A/es active IP Right Grant
- 2012-05-10 AR ARP120101655A patent/AR086344A1/es not_active Application Discontinuation
- 2012-05-10 KR KR1020137032805A patent/KR102132496B1/ko active IP Right Grant
- 2012-05-10 TW TW106130882A patent/TWI705826B/zh active
- 2012-05-10 CN CN201280034417.9A patent/CN103841992B/zh active Active
-
2013
- 2013-11-06 IL IL229276A patent/IL229276B/en active IP Right Grant
- 2013-11-08 CL CL2013003214A patent/CL2013003214A1/es unknown
- 2013-11-11 MX MX2019004264A patent/MX2019004264A/es unknown
- 2013-12-05 ZA ZA2013/09173A patent/ZA201309173B/en unknown
- 2013-12-06 CR CR20130640A patent/CR20130640A/es unknown
-
2017
- 2017-03-29 JP JP2017065349A patent/JP6400768B2/ja active Active
- 2017-09-20 AU AU2017232084A patent/AU2017232084B2/en active Active
- 2017-12-20 CL CL2017003288A patent/CL2017003288A1/es unknown
-
2018
- 2018-09-04 JP JP2018165074A patent/JP6599527B2/ja active Active
-
2019
- 2019-06-06 PH PH12019501274A patent/PH12019501274A1/en unknown
-
2020
- 2020-02-20 AU AU2020201219A patent/AU2020201219B2/en active Active
- 2020-04-03 HR HRP20200545TT patent/HRP20200545T1/hr unknown
- 2020-04-07 CY CY20201100330T patent/CY1122967T1/el unknown
- 2020-09-03 US US17/011,433 patent/US20210047434A1/en active Pending
-
2021
- 2021-03-01 IL IL281178A patent/IL281178B/en unknown
-
2022
- 2022-08-11 AU AU2022215259A patent/AU2022215259A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR086344A1 (es) | Metodos de tratamiento o prevencion de trastornos relacionados con el colesterol | |
CY1123250T1 (el) | Σταθερα σκευασματα τα οποια περιεχουν anti-pcsk9 αντισωματα | |
EA202190916A1 (ru) | Ионизируемые аминолипиды | |
EA202191559A1 (ru) | Модифицированные аминовые липиды | |
AR087305A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit | |
AR122746A2 (es) | Una formulación farmacéutica líquida estable de anticuerpo | |
PE20181365A1 (es) | Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos | |
EA201490804A1 (ru) | Препараты этанерцепта, стабилизированные хлоридом натрия | |
NZ737046A (en) | Anti-cgrp antibody formulation | |
AR103173A1 (es) | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 | |
PE20131324A1 (es) | Formulacion subcutanea de anticuerpo anti-her2 | |
MX2019003716A (es) | Formulaciones farmaceuticas de anticuerpos tnf-alfa. | |
CL2012003401A1 (es) | Compuestos derivados de carbamato de hexafluoroisopropilo, inhibidores de la enzima monoacil glicerol lipasa (mgl); proceso de preparacion; medicamento; compuestos intermediarios; composicion farmaceutica; y su uso para tratar o prevenir dolores agudos o cronicos, vertigos, dislipidemias y epilepsia, entre otras enfermedades. | |
MX2014001372A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. | |
EA201391157A1 (ru) | Антагонисты pcsk9 | |
EA201690377A1 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
PE20141019A1 (es) | Nuevos inmunoconjugados | |
MY168961A (en) | Antibodies to pcsk9 and uses thereof | |
PE20190469A1 (es) | Formulaciones, kits y metodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados | |
AR102198A1 (es) | Proceso para reducir partículas subvisibles en una formulación farmacéutica | |
PE20220337A1 (es) | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos | |
EA201991409A3 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
PE20142275A1 (es) | Formulacion de anticuerpo il-17 | |
PE20130398A1 (es) | Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo | |
AR119680A2 (es) | Métodos de tratamiento o prevención de trastornos relacionados con el colesterol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |